Gilead Sciences, Inc.’s voluntary licensing (VL) agreements for lenacapavir may have managed to take some of the sting out of the patent opposition case in India but health groups and activists don’t seem to be backing off.
They have now also flagged up apparent restrictions around supplies of active pharmaceutical ingredients (APIs) in the VL arrangements, which they believe